HC Wainwright & Co. Downgrades Soleno Therapeutics to Neutral, Lowers Price Target to $53

Benzinga Newsdesk www.benzinga.com Negative 86.5%

Neg 86.5% Neu 0% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Soleno Therapeutics (NASDAQ:SLNO) from Buy to Neutral and lowers the price target from $100 to $53.